Evidence map›Paper›PMID 42870583›Full record

ArticleHealth promotion international2026

Abolition by design: implementing the dismantling of the commercial tobacco and nicotine industry.

Raglan Maddox, Shane Kawenata Bradbrook

Abstract read
In one paragraph

Article in Health promotion international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Raglan MaddoxBagumani (Modewa) Clan, Papua New  Guinea.ORCID 0000-0002-2770-0686
Shane Kawenata BradbrookNgāi Tāmanuhiri, Rongowhakaata, Ngāti Kahungunu, Aotearoa, New Zealand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The commercial tobacco and nicotine industry continues to drive preventable disease and death globally. Despite progress in tobacco control, industry power, product diversification, market expansion, and policy interference have constrained the impact of incremental regulatory approaches. Downstream interventions, such as cessation supports and lung cancer screening, remain essential but respond to accumulated harms rather than preventing exposure at its source. This paper presents an implementation framework that positions abolition as a staged, governable, and legally supported public health strategy. Rather than a symbolic endpoint, abolition is conceptualized as a sequenced governance process through which industry structures can be dismantled using existing regulatory, fiscal, and enforcement mechanisms. These mechanisms are embedded within national systems and international instruments, including the World Health Organization Framework Convention on Tobacco Control and international human rights instruments. Abolition is mischaracterized as consumer prohibition. This reflects a category error that evaluates abolition using prohibition logics, obscuring its focus on dismantling corporate production, supply, and profit infrastructures through existing governance and regulatory tools. The framework conceptualizes the industry as an ecosystem spanning corporate structures, product categories, supply chains, science distortion, and political influence. Each domain is mapped to disruption levers and institutions, with the aim of reducing implementation risk and limiting industry adaptation. Abolition is framed as a coordinated governance project across local, national, and global levels, with Indigenous peoples and young people recognized as leaders shaping accountability, prevention pathways, and norms. This approach illustrates how abolition-oriented reform may be administratively feasible, legally defensible, and relevant to advancing health equity.

Indexed as

NicotineTobacco IndustryCommerceGovernment RegulationHumansPublic HealthTobacco ControlNicotine

Identifiers

PMID42870583
PMCPMC13662213

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.